Imaging and RNA sequencing-based radiogenomic analysis of occult lymph node metastasis and survival in lung adenocarcinoma staged non-metastatic.
[BACKGROUND] We aimed to explore the value of a PET/CT-based radiomics signature in predicting occult lymph node metastasis (OLM) and outcomes in clinical N0 (cN0) lung adenocarcinoma (LUAD), to uncov
APA
Ouyang ML, Yao YZ, et al. (2025). Imaging and RNA sequencing-based radiogenomic analysis of occult lymph node metastasis and survival in lung adenocarcinoma staged non-metastatic.. Communications medicine, 5(1), 517. https://doi.org/10.1038/s43856-025-01224-8
MLA
Ouyang ML, et al.. "Imaging and RNA sequencing-based radiogenomic analysis of occult lymph node metastasis and survival in lung adenocarcinoma staged non-metastatic.." Communications medicine, vol. 5, no. 1, 2025, pp. 517.
PMID
41258524
Abstract
[BACKGROUND] We aimed to explore the value of a PET/CT-based radiomics signature in predicting occult lymph node metastasis (OLM) and outcomes in clinical N0 (cN0) lung adenocarcinoma (LUAD), to uncover the biologic meaning of OLM-associated radiomics phenotypes and to validate the reproducibility of the identified radiomics-correlated key genes.
[METHODS] A radiomics signature for OLM prediction was developed in a training cohort and validated across multiple validation and testing cohorts in this multicenter study. Prognostic implications of the radiomics score (Radscore) were assessed by measuring recurrence-free survival. Biologic processes and pathways were enriched and correlated with Radscore and each of the 8 radiomics phenotypes using paired PET/CT and RNA sequencing data. The reproducibility of identified radiomics-associated key genes was validated using a public database, clinical tissue samples, and in vitro experiments.
[RESULTS] Here we show OLM is detected in 127 (19.9%) of 637 patients. The proposed signature achieves AUCs of 0.82, 0.81, 0.78 and 0.79 in the training, internal validation, prospective testing and external testing cohort, respectively. In addition, Radscore is identified as an independent predictive factor in predicting the risk of recurrence of LUAD. Furthermore, Radscore and OLM-related radiomics features are mostly associated with immune response. Finally, four key genes (MIR600HG, FAM13A-AS1, AQP4 and GRIA1), especially the MIR600HG gene, play important roles in OLM and prognosis of early-stage LUAD.
[CONCLUSIONS] We demonstrate that radiogenomics performed on PET/CT images provides complementary clinical, prognostic and molecular information with great potential for the prediction of OLM and risk stratification in cN0 LUAD.
[METHODS] A radiomics signature for OLM prediction was developed in a training cohort and validated across multiple validation and testing cohorts in this multicenter study. Prognostic implications of the radiomics score (Radscore) were assessed by measuring recurrence-free survival. Biologic processes and pathways were enriched and correlated with Radscore and each of the 8 radiomics phenotypes using paired PET/CT and RNA sequencing data. The reproducibility of identified radiomics-associated key genes was validated using a public database, clinical tissue samples, and in vitro experiments.
[RESULTS] Here we show OLM is detected in 127 (19.9%) of 637 patients. The proposed signature achieves AUCs of 0.82, 0.81, 0.78 and 0.79 in the training, internal validation, prospective testing and external testing cohort, respectively. In addition, Radscore is identified as an independent predictive factor in predicting the risk of recurrence of LUAD. Furthermore, Radscore and OLM-related radiomics features are mostly associated with immune response. Finally, four key genes (MIR600HG, FAM13A-AS1, AQP4 and GRIA1), especially the MIR600HG gene, play important roles in OLM and prognosis of early-stage LUAD.
[CONCLUSIONS] We demonstrate that radiogenomics performed on PET/CT images provides complementary clinical, prognostic and molecular information with great potential for the prediction of OLM and risk stratification in cN0 LUAD.